Market News 10 min read

Microchip Stock Analysis: What the Latest MCHP Results Mean for Investors

Microchip beat on both lines with net sales up 42.2% to $1.622bn, then guided December sales flat to down and gross margin lower. MCHP fell 10.02%.

A sturdy ladder with strong lower rungs but a narrow, uncertain top step, set in an open field under shifting clouds

Microchip Technology grew net sales 42.2% year on year in its September quarter and beat consensus on both lines — and the shares fell 10.02% anyway. The company's fiscal second-quarter 2027 results, released on 5 November 2026, put net sales at $1.622bn, up 42.2% from the year-ago quarter and 9.2% sequentially, with non-GAAP earnings of $0.97 per diluted share against a $0.94 consensus and a $0.93 guidance midpoint. The December-quarter guidance that came with them was the number that mattered: net sales of $1.573bn to $1.638bn, a sequential change of minus 3% to plus 1%, with non-GAAP gross margin of 64.0% to 65.0% and non-GAAP EPS of $0.87 to $0.95, a midpoint of $0.91 against the $0.97 just delivered. Shares closed 6 November at $58.35, down 10.02% from $64.85 — the second-largest decline in the S&P 500 that session.

For anyone running the numbers on Microchip, that is the whole analytical problem in two paragraphs. A business compounding at 42% has just guided to a quarter that does not grow sequentially, and the margin line goes backwards with it: 66.5% non-GAAP gross margin in September becomes 64.0% to 65.0% in December, a compression of 1.5 to 2.5 points. The company's own explanation is that approximately $53m of infrequent revenue items landed in the September quarter and do not repeat. Whether that explanation holds is the single question that decides whether this is a cyclical pause inside a recovering analog and microcontroller cycle, or the first quarter of margin give-back.

What the results actually said

Start with the quarter itself, because it was genuinely strong. Net sales of $1.622bn were a sequential record for the current upcycle and represented the continuation of a recovery that began from a much lower base. On a non-GAAP basis Microchip reported gross margin of 66.5%, operating income of $639.9m or 39.5% of net sales, net income of $559.2m and EPS of $0.97. GAAP gross margin for the same quarter was 65.9%. That distinction matters more than usual here, because the guidance is quoted on both bases — 64.0% to 65.0% non-GAAP against 62.9% to 63.9% GAAP — and comparing a non-GAAP outlook against a GAAP actual would manufacture a margin cliff that does not exist.

The September non-GAAP gross margin of 66.5% included approximately $26.6m of capacity underutilisation charges, and management attributed the strength to higher licensing revenue in the quarter plus the effect of a pricing change implemented during it. Both of those are, by their nature, the kind of help that does not recur on schedule. It is worth setting the figure against the June quarter, when non-GAAP gross margin was 63.8% and underutilisation charges were larger at $38.5m. On that comparison the December guide of 64.0% to 65.0% is not a collapse — it is roughly a return to where the margin sat two quarters ago, with less underutilisation drag but without the licensing and pricing tailwinds.

The revenue guide carries a similar double reading. A sequential range of minus 3% to plus 1% looks poor against 9.2% sequential growth just delivered. Management's framing is that stripping out the approximately $53m of infrequent September items puts the midpoint 5% to 7% better than normal seasonality for a December quarter. Both statements are true at once, which is exactly why the market had to pick one. Capital expenditure was modest — $23.1m in the September quarter, against a plan of about $100m for all of fiscal 2027 — which tells you the company is not spending into this demand as if a durable step-change in volumes were in front of it.

Why the market reacted the way it did

Semiconductor equities are priced off the second derivative, not the level. A 42% growth rate that is decelerating towards zero sequentially is treated very differently from a 15% growth rate that is accelerating, and the September print plus December guide combination said deceleration on both revenue and margin in the same breath. The 10.02% fall is the market repricing the slope of the recovery rather than disputing the quarter.

The gross margin guide did the heavier damage. Revenue guidance ranges in this industry are routinely sandbagged and routinely forgiven; a two-point step down in gross margin is harder to characterise as conservatism, because it implies something about mix, pricing or factory loading that persists beyond one quarter. Microchip has spent the past two years telling investors that margin recovery would come as utilisation improved and underutilisation charges rolled off. A quarter in which underutilisation charges fell — from $38.5m to $26.6m — and the forward margin guide still went down is a quarter that complicates that story.

The sell-side response followed the arithmetic rather than leading it: several brokers trimmed their forecasts and estimates in the days after the release. That is a lagging indicator of what the stock had already done, not an independent signal.

The Openbook read

This is where the five-factor framework earns its keep, because the September quarter and the December guide push the scores in opposite directions and a single headline cannot hold both.

Momentum is the clearest casualty. A 10.02% single-session decline, landing on a share price that has been drifting lower for months rather than rallying into the print, is a negative momentum input on both the price and the revision axis. Forward estimates for the December quarter now sit below where they were a week ago, and the non-GAAP EPS guide of $0.87 to $0.95 centres on $0.91, below the $0.97 the September quarter just delivered. Momentum scores read the direction of travel, and the direction of travel is down.

Growth remains, on the trailing data, the strongest of the five. Net sales up 42.2% year on year and 9.2% sequentially is not a weak-growth profile by any measure, and the year-on-year comparison stays flattering into the December quarter because the base period was deep in the inventory correction. The honest qualification is that a growth score built on year-on-year comparisons against a cyclical trough overstates underlying demand. The sequential series — which has just been guided flat to down — is the more informative one, and it is the series that turned first.

Profitability is the factor doing the real work in this print. Non-GAAP operating income of $639.9m at 39.5% of net sales is a genuinely high-quality margin structure for an analog and microcontroller business. But the forward guide implies non-GAAP operating profit of 37.0% to 38.5% of sales, with operating expenses at 26.5% to 27.0%, and the gross margin step down to 64.0% to 65.0% is the mechanism. A profitability score that reads the September quarter alone would be near a cycle high; one that incorporates the guide marks the peak as already behind.

Solvency is the quietest factor and, for now, the least disturbed. Nothing in this release changed the balance sheet materially, and the light capital expenditure plan — about $100m across fiscal 2027 — means free cash conversion is not about to be absorbed by fab spending. The watch item is not leverage itself but the interaction of a flat revenue quarter with a company that has historically used cash flow to service debt reduction and the dividend. One quarter of flat sales does not threaten that; a sequence of them would start to.

Reward/Risk is the factor the 10.02% move has most changed, and not in one direction. The negative case is straightforward: a de-rating on a margin guide usually comes with a second leg if the next quarter confirms it, and the $53m infrequent-revenue explanation is currently a company assertion rather than an externally verified fact. The offsetting observation is that the share price has already absorbed a double-digit single-day decline on top of a multi-month drawdown, so the quantum of bad news already in the price is materially larger than it was on 4 November. The reward/risk picture is therefore wider in both directions than it was a week ago — a higher-variance setup, not a cheaper or more expensive one. The decisive evidence arrives with the December quarter, not before.

The read-across

Microchip reports earlier in the calendar than most of its analog and microcontroller peer group, which makes this guide a data point other investors will try to generalise. It should be generalised carefully. The $53m of infrequent revenue items and the licensing contribution are Microchip-specific, and the pricing change implemented in the September quarter is a company decision rather than an industry condition. Those three things account for a meaningful part of why the September margin was as high as it was, and therefore for part of why the December guide looks like such a step down.

What does travel across the group is the structural observation underneath: in this cycle, analog and microcontroller shipments have been running ahead of end demand, and the recovery has been driven more by pricing and selective restocking than by a broad, synchronised volume upturn. A company guiding to flat-to-down sequential revenue while describing the midpoint as better than normal seasonality is describing exactly that kind of patchy recovery. Investors screening the sector on the Openbook screener should expect the same tension to show up in peers' prints — strong year-on-year numbers against a trough base, with the sequential line and the gross margin guide carrying the real information. Microchip's industrial and automotive end-market exposure overlaps most directly with Analog Devices and Texas Instruments, and the question to carry into their reports is whether their December-quarter margin guides also give back ground that utilisation gains were supposed to have won.

For the index, the move was large enough to register. Microchip was among the biggest S&P 500 decliners on 6 November, on a session when the broader market rose. That divergence is itself the read-across: this was a stock-specific repricing of a company's own margin path, not a sector-wide risk-off event.

What to watch next

  • The December quarter itself, due in early February 2027 on Microchip's usual reporting cadence. The single most important line is non-GAAP gross margin against the 64.0% to 65.0% guide — a print at or above the top of the range largely validates the infrequent-revenue explanation, and one below it does not.
  • Whether the approximately $53m of September items genuinely does not repeat. If December revenue lands in the upper half of the $1.573bn to $1.638bn range, the sequential decline was mostly arithmetic. If it lands at the bottom, the cycle explanation gains weight over the one-off explanation.
  • Capacity underutilisation charges. These fell from $38.5m in June to $26.6m in September. If they keep falling while gross margin also falls, the pressure is coming from mix and pricing rather than factory loading — a more persistent problem.
  • Capital expenditure against the roughly $100m fiscal 2027 plan. An upward revision would signal management confidence in volumes that the current guide does not express.
  • Peer December-quarter guides from the wider analog and microcontroller group over the coming weeks, which will show whether the margin give-back is Microchip's alone or the industry's.

The September quarter was a good one. The December guide is the one that will be judged, and it will be judged on a single number: whether gross margin stops at 64% or keeps going.

Was this useful?
Sign in to vote
3 of 4
Compare MCHP, TXN, ADI